TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Quick Disabilities of the Arm, Shoulder and Hand (Quick-DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Burning/Stinging
Endpoint domain: Adverse events/effects
Primary endpoint: Tearing
Endpoint domain: Adverse events/effects
Primary endpoint: Light Sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Blurred Vision
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Normal Serum Testosterone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of complications associated with the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Dermal-LSR plus SOC in treating chronic diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Dermal-LSR plus SOC in treating chronic diabetic foot ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: Change in DAS (Disease Activity Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 200m Walk-test to estimate Cardiorespiratory fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical safety and toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of prostate cancer at repeat biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plaque Index Score Per Participant at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingivitis Index Score Per Participant at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain threshold of the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in UCLA Shoulder Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: occurrence of oral mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of new persistent opioid use
Endpoint domain: Adverse events/effects
Primary endpoint: Executive Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of catechols and their metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the mid-level (elbow) dimension of the Performance of the Upper Limb (PUL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with Weight-for-height and/or Height-for-age ZScore <-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glaucoma Quality of Life 15 Questionnaire total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ 25)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short Form Physical Performance Battery (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps contractile area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: plasma concentrations of rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in symptom reports on the PAI-BOR at week 6
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in symptom severity on the Zanarini Rating Scale for Borderline Personality Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pulmonary function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Advance Care Planning note creation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Severity of Withdrawal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: 24 hours tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients with further falls
Endpoint domain: Adverse events/effects
Primary endpoint: Average total dose of BoNT-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average interval between BoNT-A injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline of the Average Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health costs after 18 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: falls after 18 months
Endpoint domain: Adverse events/effects
Primary endpoint: Bone parameters after 6, 12 and 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly SBM frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test Positivity Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of occurrence of post traumatic stress disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Time spent with blood glucose <70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Refractive data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pachymetry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment Success (IGA Score Improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in tobacco craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 1-year prevalence for each disease phase
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Total Sleep Time in Stage 2 Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Wake Time After Sleep Onset (WASO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Percent Change in Low-density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Technical Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior pelvic tilt angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-weighted SPID30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Total dose of morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Performance of non-technical skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Visual analog scale-pain of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale-pain of the ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients reporting numbness
Endpoint domain: Adverse events/effects
Primary endpoint: Sagittal balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interbody fusion(union) failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Yale Global Tic Severity Scale Total Tic Score (TTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response in Platelet Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: central arterial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: variation of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of post-transplant diabetes in subjects without CFRD
Endpoint domain: Adverse events/effects
Primary endpoint: Bone mineral density after one year of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Corrected calcium after 3 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CTX after 3 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients With Undetectable PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite end-point of mortality or re-intervention
Endpoint domain: Mortality/survival
Primary endpoint: blood oxygen level dependent (BOLD) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With At Least One Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: rates of walled off necrosis resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of walled off necrosis related death
Endpoint domain: Mortality/survival
Primary endpoint: number of hospital readmissions during treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Inflammation and oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of antibiotic concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in family quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Timed 25 Foot Walk (T25FW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of GSK1014802 following a single oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of GSK1014802 following repeated oral doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of structured assessment of social interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Provider EBP knowledge and MI skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change In Provider Self-Efficacy for EBP Implementation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Youth Substance Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence rate of adverse events in single ascending doses (SAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of adverse events in multiple ascending doses (MAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline of T Cell miRNA Expression at 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Curve (AUC) at Steady State for Metronidazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) at Steady State for Metronidazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients with No Moderate or Severe Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ongoing Pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Rate of patients admitted to the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Anxiety Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in level of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived barriers to care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Correct placement of endotracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean change in hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean change in weekly epoetin dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (AEs): incidence and severity of all drug-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: percent one-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability of RAD001
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of RAD001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of positive surgical margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cardiovascular Diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV/HCV testing uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: response rate on PET scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 forced expiratory volume-one second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FVC forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in 24-hour weighted mean blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of the tuberculosis vaccine FP85A
Endpoint domain: Adverse events/effects
Primary endpoint: Validity of Caregiver Functional Use Survey (CFUS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality 24 hours after birth
Endpoint domain: Mortality/survival
Primary endpoint: Days with fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days with cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days with asthenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: papillary recession reduction (pRecRed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage papillary coverage (PPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical response at test-of-cure visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of glucose metabolism alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: toxicity of escalating doses of decitabine
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness Handicap Inventory (DHI) change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Goniometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likert muscle Soreness Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Ratio of Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Ratio of AUCt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Y-BOCS Change Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary efficacy endpoint at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary efficacy endpoint at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Naringenin pharmacokinetic curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Specific Health Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-Efficacy to Manage Stroke Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability to Complete the Entire 12 Week Study on Study Drug
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Severity of Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Excretion of Aquaporin-2 in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of developmental quotient below 70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Number and proportion of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Leukocytes Infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of necrosis of the AK lesion and skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of nasal ILCs after COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of adverse events requiring surgical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of lead migration
Endpoint domain: Adverse events/effects
Primary endpoint: Sleepiness severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Quality of life in epilepsy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: All cause harmful events
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Pathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With at Least a 1-Grade Reduction at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least a 2-Grade Reduction at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Submental Skin Laxity Grade Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facemask acceptance during drug delivery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effect of sedation on children's future behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Post-operative effects of the sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgo-sedative effect of each drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amnesic effect of sedative agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of cutaneous hyperalgesia and allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain in perineal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: death from haemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Residual Renal Function (RRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Acute Thermal Injury Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunohistochemical analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence-free Survival Time
Endpoint domain: Mortality/survival
Primary endpoint: Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mindful Attention Awareness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Connor-Davidson Resilience Scale 10 (CD-RISC-10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with grade 2 or higher xerostomia
Endpoint domain: Adverse events/effects
Primary endpoint: immunological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnosis and classification of venous blood clots
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Development of chronic complications of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes in mood ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: changes in short-term recognition memory ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in attention ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes